Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice

Aim: To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the treatment of Huntingtons disease (HD)-like symptoms in mice. Materials \& methods: EGCG was incorporated into PEGylated poly(lactic-co-glycolic) acid NPs with ascorbic acid (AA). HD-like striatal le...

Full description

Bibliographic Details
Main Author: Cano, Amanda (author)
Other Authors: Ettcheto, Miren (author), Espina, Marta (author), Auladell, Carmen (author), Folch, Jaume (author), Kühne, Britta A (author), Barenys, Marta (author), Sánchez-López, Elena (author), Souto, Eliana B. (author), García, Maria Luisa (author), Turowski, Patric (author), Camins, Antonio (author)
Format: article
Language:eng
Published: 2020
Subjects:
3-nitropropionic acide
pigallocatechin-3-gallate
Huntingtons disease
neurodegenerative diseases
PLGA-PEG
polymeric nanoparticles
3-nitropropionic acid
epigallocatechin-3-gallate
Ciências Naturais::Ciências Biológicas
Science & Technology
Online Access:http://hdl.handle.net/1822/74411
Country:Portugal
Oai:oai:repositorium.sdum.uminho.pt:1822/74411
Description
Summary:Aim: To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the treatment of Huntingtons disease (HD)-like symptoms in mice. Materials \& methods: EGCG was incorporated into PEGylated poly(lactic-co-glycolic) acid NPs with ascorbic acid (AA). HD-like striatal lesions and motor deficit were induced in mice by 3-nitropropionic acid-intoxication. EGCG and EGCG/AA NPs were co-administered and behavioral motor assessments and striatal histology performed after 5 days. Results: EGCG/AA NPs were significantly more effective than free EGCG in reducing motor disturbances and depression-like behavior associated with 3-nitropropionic acid toxicity. EGCG/AA NPs treatment also mitigated neuroinflammation and prevented neuronal loss. Conclusion: NP encapsulation enhances therapeutic robustness of EGCG in this model of HD symptomatology. Together with our previous findings, this highlights the potential of EGCG/AA NPs in the symptomatic treatment of neurodegenerative diseases.

Similar Items